Search Results

HistoSonics® announced that the company’s Edison System has been selected to participate in the UK’s newly created Innovative Devices Access Pathway Pilot Program designed to accelerate the development of cost-effective medical devices and their integration into the UK market.

HistoSonics, Inc., (www.histosonics.com), developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the treatment of the first patient in its pivotal #HOPE4KIDNEY Trial.

HistoSonics, the manufacturer of the non-invasive Edison® Histotripsy System and novel sonic beam therapy, announced that the Centers of Medicare & Medicaid Services set a new payment rate for histotripsy of liver tumors procedures, increasing the payment rate to $17,500.

HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today the marketing authorization of its “Breakthrough” platform via the U.S. Food and Drug Administration’s (FDA) De Novo Classification Request process, a rigorous pre-market review pathway for medical devices with no existing predicate.

HistoSonics, the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced the first kidney patient has been treated using the Company’s histotripsy platform.

HistoSonics, (www.histosonics.com) announced today the US Food and Drug Administration (FDA) has approved the company sponsored #HOPE4KIDNEY Trial which is designed to evaluate the safety and technical success of the Edison System in targeting and destroying targeted primary renal tumors, completely non-invasively and without the need for incisions or needles.

HistoSonics announced today the publication of results from their prospective Phase I clinical trial, named the THERESA Trial, conducted in Barcelona, Spain.

HistoSonics, (www.histosonics.com), the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform.

HistoSonics, is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver.

HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval to initiate the company’s second European clinical trial of its new platform technology